ZEAL News & Analysis
3 articles
Market Mood
Zealand Pharma (ZEAL) Stock Drops 23% on Survodutide Data Concerns
Zealand Pharma (ZEAL) shares fell 23% after revealing that its weight loss drug, survodutide, had a patient dropout rate of 19%, leading analysts to cut peak sales forecasts by nearly 80%. The stock has declined 38% year-to-date and experienced its worst trading days on record since going public in 2010. UBS analysts reduced their price target from 730 to 540 Danish kroner while maintaining a Buy recommendation, focusing on the next potential driver, petrelintide. Although the company faces competition, analysts see promise in amylin drugs like petrelintide that meet the demand for high tolerability.
Read More
Zealand Pharma (ZEAL) Stock Drops 23% After Safety Data Report
Zealand Pharma's (ZEAL) shares fell 22.7% after new safety data revealed a 19% dropout rate in a trial for its drug, survodutide, due to gastrointestinal side effects. This represents an increase from the 2.9% dropout rate with a placebo. The high discontinuation rate, coupled with over 40% of participants experiencing symptoms like vomiting, raises concerns about the drug's commercial viability. Year-to-date, Zealand's shares have dropped nearly 50%, making the latest results significant as competition in the weight loss drug market intensifies.
Read More
Zealand Pharma (ZEAL) Q1 2026 Earnings Beats Expectations
Zealand Pharma (ZEAL) reported its earnings for Q1 2026, surpassing market expectations with a notable increase in revenue. The company achieved a revenue of $45 million, which represents a 15% increase compared to the previous quarter. This performance is significant as it indicates strong demand for its products and solid market positioning. Analysts have noted that the growth may positively influence investor sentiment and stock performance moving forward.
Read More